PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients
NCT: NCT06321757 · RECRUITING
Brief Summary
Post-market, prospective, observational, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon (DCB)therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A percutaneous coronary intervention (PCI) with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician.
Frequently Asked Questions
What is PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients?
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients is a clinical trial registered under NCT06321757. Current status: RECRUITING.
What is the status of NCT06321757?
The current status of NCT06321757 (PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients) is: RECRUITING.
When did PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients start?
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients started on 2024-02-26.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.